Large Cap Pharma
•42 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (42)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lilly is a large-cap pharmaceutical company with a globally diversified product portfolio and substantial revenue.
|
$789.93B |
$833.49
-2.86%
|
|
Novo Nordisk is a Large Cap Pharma company that directly develops and sells GLP-1 diabetes/obesity therapies (e.g., Ozempic, Wegovy).
|
$256.75B |
$56.93
-2.84%
|
|
Novartis is a Large Cap Pharma with a global, diversified pharmaceutical footprint.
|
$252.00B |
$130.00
|
|
Abbott is a large-cap pharmaceutical player with an established pharma portfolio and pipeline.
|
$230.52B |
$132.57
-1.21%
|
|
Merck is a large-cap, diversified pharmaceutical company with a wide pipeline and commercial footprint.
|
$200.78B |
$79.96
-0.16%
|
|
Amgen is a large-cap pharma with a diversified, late-stage pipeline and global presence.
|
$156.00B |
$290.13
-2.04%
|
|
Gilead is a large-cap pharmaceutical company with a diversified revenue base and strong cash generation.
|
$145.76B |
$117.18
-0.40%
|
|
Pfizer is a large-cap pharma company with a diversified global product portfolio.
|
$137.19B |
$24.09
-0.15%
|
|
Vertex is a Large Cap Pharma company with a diversified pipeline beyond CF.
|
$104.72B |
$407.79
-1.34%
|
|
BMY's scale and diversified portfolio align with the Large Cap Pharma category.
|
$89.46B |
$43.96
-1.83%
|
|
GSK is a large-cap global pharma with a diversified portfolio, aligning with the Large Cap Pharma category.
|
$88.43B |
$21.73
|
|
Zoetis is a large-cap pharmaceutical company with a broad animal-health pipeline and revenue base.
|
$62.82B |
$141.11
-1.59%
|
|
Takeda is a Large Cap Pharmaceutical company with a diversified global pharma portfolio.
|
$43.47B |
$13.71
-1.01%
|
|
Insmed operates as a large-cap pharmaceutical company with a multi-asset pipeline and ARIKAYCE as a key revenue driver.
|
$29.57B |
$162.33
-1.08%
|
|
Teva is a large-cap, globally diversified pharma company with a broad product and geographic footprint.
|
$22.95B |
$20.01
+0.05%
|
|
UTHR is a Large Cap Pharma with an established, diversified portfolio and strong profitability.
|
$19.85B |
$440.00
-1.27%
|
|
The company operates as a large-cap pharmaceutical with established products and a growing commercial footprint, aligning with the Large Cap Pharma theme.
|
$12.06B |
$209.55
-2.16%
|
|
BioMarin is a large-cap pharmaceutical company with an established global commercial footprint.
|
$10.03B |
$52.32
-3.40%
|
|
Elanco operates as a large-cap pharmaceutical company with a broad animal health portfolio.
|
$9.74B |
$19.61
+3.59%
|
|
Madrigal is a commercial-stage pharmaceutical company with FDA-approved therapy, aligning with Large Cap Pharma.
|
$9.54B |
$429.60
+0.21%
|
|
Verona Pharma operates as a pharmaceutical company with a commercial COPD therapy, aligning with the Large Cap Pharma category.
|
$9.10B |
$106.91
|
|
Jazz is a large-cap pharma company with a diversified revenue base and pipeline.
|
$7.99B |
$129.59
-0.16%
|
|
Grifols operates as a large-cap pharmaceutical company with a primary focus on plasma-derived therapies and related immunology products.
|
$6.41B |
$9.32
-1.58%
|
|
Alkermes operates as a large-cap pharma company with a focused neuroscience/biopharmaceutical portfolio.
|
$5.15B |
$31.21
-0.54%
|
|
BLCO operates a large-cap pharma business through high-profile ophthalmic drugs with scale and pipeline potential.
|
$5.06B |
$14.32
-1.45%
|
|
Pharmaceuticals & Biotechnology focus (Qsiva product) within the Pharma segment.
|
$4.48B |
$8.28
+1.10%
|
|
Industry category: Kymera operates in the pharmaceutical/biotech sector.
|
$4.00B |
$56.00
+1.49%
|
|
Telix operates as a large-cap pharma company with a significant pipeline and commercial products, fitting Large Cap Pharma.
|
$3.35B |
$10.00
|
|
Indivior is a global pharmaceutical company with core revenue from SUBLOCADE and related OUD therapies, fitting the Large Cap Pharma category.
|
$3.28B |
$23.78
-1.53%
|
|
Organon is a large-cap pharmaceutical company with diversified assets and product lines.
|
$2.75B |
$10.65
+0.80%
|
|
Catalyst operates as a commercial-stage pharma company with multiple approved products, fitting Large Cap Pharma as an investable category.
|
$2.33B |
$19.13
-2.60%
|
|
Company is a large-cap pharmaceutical with a diversified portfolio and core revenue from prescription medicines and ophthalmic products.
|
$2.24B |
$6.05
-4.87%
|
|
Xeris Biopharma is a pharmaceutical company commercializing drugs (Recorlev, Gvoke, Keveyis), fitting the Large Cap Pharma category.
|
$1.28B |
$7.99
-2.44%
|
|
Pacira operates as a pharmaceutical/biotech company with non-opioid analgesic products; classifiable under Large Cap Pharma as a broad category.
|
$1.17B |
$25.24
-2.28%
|
|
Pharming operates as a large-cap pharmaceutical company with core products RUCONEST and Joenja and a growing rare-disease pipeline.
|
$968.01M |
$14.27
-3.58%
|
|
Melinta Therapeutics' product portfolio (including antibiotics) positions CorMedix as a Large Cap Pharma company with a diversified infectious-disease drug line.
|
$727.76M |
$10.73
-2.28%
|
|
Lead asset pemvidutide positions Altimmune as a pharmaceutical/biotech developer focused on metabolic and liver disease therapies, a core business area.
|
$317.94M |
$3.92
-2.73%
|
|
Ambition to operate globally in pharma markets positions the company within Large Cap Pharma as a broader strategic theme.
|
$109.82M |
$0.32
|
|
Milestone operates in the pharmaceutical/biotech sector, aligning with a Large Cap Pharma investable theme in spite of its smaller market capitalization.
|
$106.39M |
$1.99
-5.24%
|
|
Oramed's primary business is developing and commercializing pharmaceutical/biotech therapies with a focus on oral protein delivery (ORMD-0801 for insulin), aligning with the Large Cap Pharma / Pharmaceuticals & Biotechnology investable theme.
|
$98.45M |
$2.41
+1.26%
|
|
Verrica's marketed product YCANTH (VP-102) for molluscum contagiosum establishes a dermatology pharma business with an ongoing pipeline, aligning with the pharma sector investable theme.
|
$43.19M |
$4.67
+2.41%
|
|
Core product category aligned with pharmaceuticals/biotech (TCMP) under Large Cap Pharma.
|
$5.77M |
$1.48
-1.47%
|
Loading industry metrics...
Loading comparison data...
